Why the study?
Does ischemic preconditioning improve myocardial function and diminish infarction in ischemic heart disease?
Does ischemic preconditioning improve myocardial function and diminish infarction in ischemic heart disease?
Understanding the mechanisms of ischemic preconditioning, particularly the role of PKC, may lead to novel routine treatments to salvage ischemic myocardium in patients with ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Does not support clinical adoption of ischemic preconditioning; leaves open PKC pathway translation to therapies in ischemic heart disease.
In the phenomenon termed "ischemic preconditioning," a brief period of ischemia prior to a more prolonged one improves myocardial function (after reperfusion) and diminishes infarction. This phenomenon has been described extensively in experimental animals and now in humans. It is triggered by several agents released by ischemic cells and can be reproduced by infusion of agonists coupled to protein kinase C (PKC), e.g. adenosine, angiotensin, phenylephrine, bradykinin, and endothelin. The intracellular signaling pathway involves a phospholipase, either C or D, which metabolizes membrane phospholipids to produce diacylglycerol, a necessary endogenous cofactor for PKC activation. Which protein(s) is phosphorylated by PKC is not yet known, nor is the identity of the end-effector that actually mediates protection of the ischemic cell. Identification of the end-effector may make it possible in the routine treatment of patients with ischemic heart disease to precondition and thereby salvage ischemic myocardium and improve survival.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: